使用替诺福韦二磷酸水平预测人类免疫缺陷病毒(HIV)感染女性产后病毒血症:一项巢式病例对照研究
在产后抗逆转录病毒治疗(ART)策略试验中开展巢式病例对照研究,61例病例和20例对照贡献365对干血斑-病毒载量样本;替诺福韦二磷酸(TFV-DP)<700 fmol/punch预测未来病毒血症的敏感度为62.9%、特异度为89.7%;调整后TFV-DP 350-699和<350 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比分别为3.5和12.9;作者认为TFV-DP与未来病毒血症强相关,似有助于识别不依从并预测未来病毒载量升高。
要点
- 产后HIV感染女性中,TFV-DP<700 fmol/punch预测未来病毒血症的敏感度62.9%、特异度89.7%。
- 调整后TFV-DP 350-699 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比为3.5。
- 仅分析病毒抑制期样本时,TFV-DP<350 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比为9.5。
核心结论
- 干血斑中TFV-DP浓度与未来病毒血症强相关,作者认为似有助于识别不依从并预测未来病毒载量升高。
研究设计与样本
- 在产后ART给药策略试验内开展巢式病例对照研究;参与者妊娠期开始含替诺福韦二酯(TDF)的ART,产后<10周且病毒载量<400 copies/mL。
- 病毒载量和TFV-DP样本每3-6个月采集一次,共24个月;病例为≥1次病毒载量≥20 copies/mL者,对照从持续病毒抑制(病毒载量<20 copies/mL)女性中随机抽取。
- 共61例病例和20例对照,贡献365对干血斑-病毒载量样本,中位ART时长16个月。
主要发现
- TFV-DP<700 fmol/punch检测未来病毒血症的敏感度为62.9%(95% CI,54.7-70.6%),特异度为89.7%(95% CI,84.9-93.4%)。
- 调整年龄、ART时长、既往病毒载量及TFV-DP与病毒载量检测间隔后,TFV-DP 350-699 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比为3.5(95% CI,1.1-10.8;P = .033)。
- 调整后TFV-DP<350 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比为12.9(95% CI,3.6-46.6;P < .0001)。
- 仅纳入病毒抑制期样本时,TFV-DP<350 fmol/punch相比≥1850 fmol/punch的未来病毒血症似然比为9.5(95% CI,1.9-47.0)。
临床怎么用
- 作者认为干血斑TFV-DP浓度似有助于识别不依从并预测未来病毒载量升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are few data on the utility of tenofovir diphosphate (TFV-DP) in dried blood spots (DBSs) to predict future viral load (VL) in postpartum women with HIV on antiretroviral therapy (ART). METHODS: We conducted a nested case-control study within a trial of postpartum ART delivery strategies. Participants started ART containing tenofovir disoproxil fumarate (TDF) in pregnancy, were <10 weeks postpartum, and had a VL <400 copies/mL. VL and TFV-DP samples were taken every 3-6 months over 24 months. Cases had ≥1 VL ≥20 copies/mL; controls were randomly sampled from women with persistent viral suppression (VS; VL <20 copies/mL). Generalized estimating equations were used to calculate likelihood odds ratios (LORs) for future VL ≥20 copies/mL by TFV-DP concentration at the preceding visit. RESULTS: 61 cases and 20 controls contributed 365 DBS-VL pairs (median ART duration, 16 months). Sensitivity and specificity of TFV-DP <700 fmol/punch to detect future viremia were 62.9% (95% CI, 54.7-70.6%) and 89.7% (84.9-93.4%), respectively. Adjusting for age, ART duration, previous VL, and duration between the TFV-DP and VL measures, LORs of viremia for TFV-DP concentrations 350-699 and <350 fmol/punch versus TFV-DP ≥1850 fmol/punch were 3.5 (95% CI, 1.1-10.8; P = .033) and 12.9 (3.6-46.6; P < .0001), respectively. Including only samples taken during VS, the LOR of future viremia for TFV-DP concentration <350 fmol/punch versus TFV-DP ≥1850 fmol/punch was 9.5 (1.9-47.0). CONCLUSIONS: TFV-DP concentrations in DBSs were strongly associated with future viremia and appear useful to identify nonadherence and predict future elevated VL.
引用
- Odayar J, Orrell C, Phillips TK, et al. Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study. Clin Infect Dis. 2022. PMID: 34979553. doi:10.1093/cid/ciab1068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。